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Summary In order to unravel possible mechanisms of clinical resistance to topoisomerase inhibitors, we developed a topotecan-resistant
human IGROV-1 ovarian cancer cell line, denoted IGROVTlOOr, by stepwise increased exposure to topotecan (TPT). The IGROVT100r cell line
was 29-fold resistant to TPT and strongly cross-resistant to SN-38 (51-fold). However, the IGROVTlOOr showed only threefold resistance to
camptothecin (CPT). Remarkably, this cell line was 32-fold resistant to mitoxantrone, whereas no significant cross-resistance against other
cytostatic drugs was observed. No differences in topoisomerase protein levels and catalytic activity as well as topoisomerase cleavable
complex stabilization by CPT in the IGROV-1 and IGROVTIOOr cell lines were observed, indicating that resistance in the IGROVTlOOr cell line
was not related to topoisomerase I-related changes. However, resistance in the resistant IGROVTlOOr cell line to TPT and SN-38 was
accompanied by decreased accumulation of the drugs to approximately 15% and 36% of that obtained in IGROV-1 respectively. No reduced
accumulation was observed for CPT. Notably, accumulation of TPT in the IGROV-1 cell line decreased under energy-deprived conditions,
whereas the accumulation in the IGROVTlOOr cell line increased under these energy-deprived conditions. The efflux of TPT at 370C was very
rapid in the IGROV-1 as well as the IGROVT100r cell line, resulting in 90% efflux within 20 min. Importantly, the efflux rates of TPT in the
IGROV-1 and IGROVTlOOr cell lines were not significantly different and were shown to be independent on P-glycoprotein (P-gp) or multidrug
resistance-associated protein (MRP). These results strongly suggestthat the resistance ofthe IGROVTlOOr cell line to TPT and SN-38 is mainly
caused by reduced accumulation. The reduced accumulation appears to be mediated by a novel mechanism, probably related to impaired
energy-dependent uptake of these topoisomerase drugs.
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DNA topoisomerase I (topo I) catalyses changes in DNA topology
through cycles of transient DNA strand breaks and religations
(Wang, 1985; Garg et al, 1987; Liu, 1989). During these events, a
covalent complex, the so-called cleavable complex, is formed.
Topo I-inhibiting anti-cancer agents, e.g. camptothecin (CPT) are
capable ofstabilizing the cleavable complex formed by topo I, and
inhibit the DNA function oftopo I (Gallo et al, 1971; Hsiang et al,
1985; Hsiang et al, 1989). Drug treatment results in inhibition of
DNA replication and chromosomal fragmentation. Because of
practical and clinical problems associated with CPT, a number of
derivatives have been developed in recent years, e.g. irinotecan
(CPT-11) and its active metabolite SN-38, TPT, 9-aminocampto-
thecin (9-AC) and GI-147211 (Sinha, 1995). These drugs show a
broad spectrum of anti-cancer activity in preclinical and clinical
studies (Giovanella et al, 1989; Rowinsky et al, 1992; Slichenmyer
et al, 1993; Potmesil, 1994; Rowinsky et al, 1994; Tanizawa et al,
1994; Sinha, 1995; Conti et al, 1996). However, tumours may
develop clinical resistance against these topo I inhibitors. For this
reason, studies on the mechanisms ofresistance to topo I inhibitors
are warranted.
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Several topo I inhibitor resistant cell lines have been established
(Andoh et al, 1987; Eng et al, 1990; Kanzawa et al, 1990;
Sugimoto et al, 1990; Hendricks et al, 1992; Madelaine et al, 1993;
Pantazis et al, 1994; Fujimori et al, 1995; Sorensen et al, 1995).
The mechanism of resistance has often been ascribed to various
topo I-related changes, e.g. (1) reduced topo I catalytic activity
(Madelaine et al, 1993; Fujimori et al, 1995; Sorensen et al, 1995),
(2) decreased formation of cleavable complexes (Madelaine et al,
1993; Fujimori et al, 1995), (3) decreased expression of topo I
(Eng et al, 1990; Sugimoto et al, 1990) and (4) a point mutation or
rearrangement of topo I genes (Andoh et al, 1987; Fujimori et al,
1995). Reduced accumulation of TPT, due to P-glycoprotein (P-
gp) overexpression, has been reported to add to resistance to topo I
inhibitors as well (Hendricks et al, 1992; Mattern et al, 1993;
Hasegawa et al, 1995). Moreover, TPT is also a substrate for the
multidrug resistance-associated protein (MRP) (Maliepaard et al,
1996). Importantly, resistance to CPT does not appearto be related
to P-gp or MRP (Hendricks et al, 1992; Mattem et al, 1993;
Maliepaard et al, 1996). This difference between TPT and CPT
may be partly caused by positive charge of TPT at physiological
pH, although other factors may also be important in this respect
(Mattern et al, 1993).
In this paper, we report the development and characterization of
a TPT-resistant human IGROV-1 ovarian cancer cell line that is
highly cross-resistant to SN-38, but displays only minor resistance
to CPT. The acquisition ofresistance was associated with reduced
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cellular accumulation rather than changes of topo I catalytic
activity or cleavable complex formation. This reduced accumula-
tion was shown to be independent ofP-gp or multidrug resistance-
associated protein (MRP). Because of these characteristics, this
cell line appears to be a valuable model for studying the mecha-
nisms ofresistance to topo I inhibitors.
MATERIALS AND METHODS
Chemicals and drugs
CPT was obtained from Aldrich (Bornem, Belgium). TPT was a
generous gift from Smith Kline Beecham Pharmaceuticals (King
of Prussia, PA, USA). SN-38 was generously supplied by Rhone-
Poulenc Rorer (Alfortville, France). Plasmid pBR322 DNA,
sulforhodamine B (SRB), DL-buthionine-(S,R)-sulfoximine (BSO)
and agarose were obtained from Sigma (St Louis, MO, USA), and
kinetoplast DNA (kDNA) and scleroderma human topo I antibody
from TopoGEN (Columbus, Ohio, USA). Doxorubicin (DOX)
was obtained from Pharmacia (Brussels, Belgium). Cis-
diamminedichloroplatinum(II) (cisplatin, CDDP), mitoxantrone
(MX) and methotrexate (MTX) were obtained from Lederle
(Wolfratshausen, Germany). Paclitaxel (Taxol) andetoposide (VP-
16) were purchased from Bristol Myers (Troisdorf, Germany) and
5-fluorouracil (5-FU) from Roche (Mijdrecht, The Netherlands).
Verapamil (VPL) was obtained from Bufa (Uitgeest, The
Netherlands). RPMI 1640 medium was obtained from GibcoBRL
(Life Technologies, Breda, The Netherlands) and phosphate-
buffered saline (PBS, Dulbecco 'A') was from Unipath
(Basingstoke, UK). Bovine calf serum (BCS) was purchased from
Hyclone (Logan, Utah, USA) and the actin monoclonal antibody
(MAb) from Boehringer Mannheim (Almere, The Netherlands).
The P-glycoprotein-specific MAb C219 was obtained from Cis
Biointemational (Gif-sur-Ivette, France) and the MRP-specific
MAb MRPrl was kindly provided by Dr R Scheper (Flens et al,
1994) (Department ofPathology, Free University, Amsterdam).
Cell lines and development of resistance
The human ovarian cancer IGROV-1 and the TPT-resistant
IGROVT,OOr cells were cultured in Hepes-buffered RPMI 1640
medium, supplemented with 10% Bovine Calf Serum (BCS),
10 mm sodium bicarbonate, 2 mM glutamine, gentamycin, peni-
cillin, streptomycin and phenol red in a humidified atmosphere of
5% carbon dioxide at 37°C. The TPT-resistantIGROVTIM cell line
was developed by continuous exposure toTPT. The starting concen-
tration of TPT used for incubation was 12 nM (5 ng ml-'). Fresh
medium, containing TPT, was added every week. The TPT concen-
tration was increased stepwise to 24, 48, 96 and finally to 235 nrm
after 5 months ofculturing. The cells were passaged at 235 nm TPT
for another 4 months, after which TPT was withdrawn. No change
in TPT resistance was observed after withdrawal ofTPT for at least
3 months. The cells were frequently monitored for mycoplasma
contamination, using the Hoechst 33258 dye colouring method.
Assessment of cytotoxicity and cross-resistance
The cytotoxicity ofTPT, SN-38, CPT, DOX, VP-16, CDDP, pacli-
taxel, 5-FU, MX and MTX against the IGROV-1 and IGROVT,OOr
cells was estimated using the SRB assay (Skehan et al, 1990).
Stock solutions of TPT (1.0 mg ml-') were prepared in Millipore
water. SN-38 and CPT were dissolved in dimethyl sulphoxide
(DMSO) at a concentration of 1.0 mg ml-', whereas DOX, VP-16,
CDDP, 5-FU, MX and MTX were dissolved in 0.9% sodium chlo-
ride (at concentrations of 2.0, 20, 1.0, 50, 2.0 and 2.5 mg ml-'
respectively). Paclitaxel was applied as the clinical formulation
Taxol, i.e. dissolved at a concentration of 6.0 mg ml-1 in
EtOH/Cremophor EL 1:1. All drugs were diluted in RPMI
medium just before the start of the incubation. TPT, SN-38 and
CPT were prediluted twofold with 0.1% acetic acid to convert the
compounds into their active lactone form. Cells (2 x 103 cells per
well) were plated in 96-well plates and pre-incubated for 48 h at
37°C. On day 2, serial threefold dilutions of drug were added,
yielding concentrations ranging from 0.08 ng ml-' to 500 ng ml-',
or 2.1 to 13 500 ng ml', depending on the IC50-values observed in
pilot experiments, and cells were incubated for 5 days.
Subsequently, cells were fixed with 10% trichloroacetic acid and
put at 4°C for 1 h. After thorough washing with water, the cells
were stained for at least 15 min with 0.4% sulforhodamine B
(SRB), dissolved in 1% acetic acid. After this incubation period,
the cells were washed with 1% acetic acid to remove unbound
stain. The plates were air dried, and the bound protein stain was
dissolved in 150 gl of 10 mm Tris buffer, pH 7.3. Absorbance was
read at 540 nm, using a Model 450 Microplate reader (Bio-Rad
Laboratories, CA, USA).
P-gp and MRP expression
Immunocytochemical detection of P-gp and MRP was performed
according to previously used procedures (Sonneveld et al, 1992;
Nooter et al, 1995). Cytospin preparations were fixed in cold
acetone (10 min, 0C), air dried and incubated with the MRP-
specific MAb MRPrl or with the P-gp-specific MAb C219.
Antibody binding was detected using alkaline phosphatase-conju-
gated immunoglobulin (Dako, Copenhagen, Denmark) and alka-
line phosphatase substrate using new fuchsine (Dako). The slides
were counterstained with haematoxylin and mounted. The speci-
ficity of C219 and MRPrl has been documented in detail else-
where (Grogan et al, 1990; Flens et al, 1994). Before use, C219
and MRPrl were diluted (1:10 and 1:1500 respectively) in Tris-
buffered saline (50 mm Tris pH 7.4) containing normal rabbit
serum (10%, w/v), normal goat serum (1%, w/v) and normal
human AB serum (1%, w/v). Each assay included the use of an
isotype-matched irrelevant MAb (mouse IgG2a and rat IgG2a,
respectively, for C219 and MRPrl).
Topo I protein levels and catalytic activity
IGROV-1 and IGROVTI,Or cells in logarithmic growth were
harvested and denatured in 62.5 mm Tris, 10% glycerol, 2.5%
sodium dodecyl sulphate (SDS), 5% 3-mercaptoethanol, 0.005%
bromophenol blue and 0.5 mg ml-1 Pefablock, at 100°C for 5 min.
After separation of the proteins on a 10% polyacrylamide gel,
proteins were electrophoretically transferred to PVDF immubolin
membranes (Millipore, Bedford, MA, USA). Proteins were
hybridized using topo I and actin antibodies. Actin was included as
control forprotein loading foreach sample. Spots were quantitated
using a phosphor imaging system (Fujix Bas 2000).
Nuclear extracts were prepared as described (van der Zee et al,
1991). Topo I catalytic activity in these nuclear extracts was
assayed by monitoring the relaxation ofsupercoiled pBR322 DNA
(250 ng) (Liu and Miller, 1981). Samples were analysed by
electrophoresis on a 1% agarose gel. After staining the gels with
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Figure 1 Growth inhibition curves of IGROV-1 (0) and IGROVTO,Or 0).
Cells were incubated with TPT for 5 days. Cytotoxicity of TPT was assessed
using the SRB assay, as described in Materials and methods
Table 1 Cross resistance pattern of IGROVT1,0r
Drugs IGROV-1 IGROVTloor Rfa P-value
IC50 (nM) IC50 (nm)
TPT 16.1 ±4.0 472± 117 29.3±6.9 <0.001
SN-38 3.3+ 1.3 168±69 51 ±17 0.02
CPT 6.6+ 2.2 16.9 ± 2.9 2.6 ± 0.4 0.008
DOX 96 ±45 94 ±39 1.0 ±0.2 NSb
VP-16 776
+ 228 1025 ±172 1.3 ±0.2 NS
CDDP 253 ±81 517 ±182 2.0 ±0.6 NS
Paclitaxel 35 ±15 35 ±13 1.0 ±0.1 NS
5-FU 483±103 371 ±137 0.8±0.2 NS
MX 9.2±2.7 295± 134 32.1 ±9.6 0.02
MTX 31.5+5.3 12.1 ±1.1 0.4±0.0 0.003
aRf, resistance factor, determined with the SRB method.bNS, not significant.
Data are means ± s.d from at least three experiments.
ethidium bromide, the bands were visualized over an UV light table
and photographed with Polaroid (667) positive/negative films.
The stabilization of topo I cleavable complexes by CPT was
determined by incubating reaction mixtures at 370C for 30 min
with concentrations of CPT ranging from 3 to 200 gM, as
described (Hsiang et al, 1985). The reaction mixtures contained
the lowest amount of nuclear proteins that was able to yield
complete relaxation of250 ng ofpBR322 DNA. Reaction products
were separated on 1% agarose gel and visualized as described
above. Each experiment was performed in triplicate.
Intracellular accumulation of TPT, SN-38 and CPT
Accumulation of TPT, SN-38 and CPT was measured in IGROV-I
and IGROVTlI cells that were grown to 50-70% confluency
(approximately 2-3 x 106 cells per flask) in T25 tissue culture
flasks (Greiner, Alphen a/d Rijn, The Netherlands). The cells were
incubated for 30 min at 370C with 0.95 or 1.90 gM TPT, 1.02 or
2.04gM SN-38 and 1.15 or 2.30 gM CPT (equals 400 or
800 ng ml-1 for all compounds). Incubation of IGROV-1 and
IGROVTIOOr cells with these concentrations of topo I inhibitors did
not result in morphological changes of the cells. After incubation,
cells were washed twice with ice-cold PBS and scraped immedi-
ately. The cells were collected in a glass tube and centrifuged (5
min, 500 g, 4'C). Subsequently the cells were resuspended in 150
gl of0.1% acetic acid to lyse the cells. Protein concentrations were
determined using the Bio-Rad assay based on the Bradford method
(Bradford, 1976). The concentration of TPT in the sample was
measured using a previously described sensitive high-performance
liquid chromatography (HPLC) method (Loos et al, 1996). Topo I
inhibitors, such as TPT, exist in equilibrium between the lactone
and the hydroxy-acid form (Beijnen et al, 1990), of which the
lactone is the active form. The equilibrium between the TPT
lactone and the hydroxy-acid form is pH dependent. At pH 7.5,
eventually, approximately 90% of total TPT will be in the
hydroxy-acid form, whereas, at pH 5.0, this is only approximately
10%. Preliminary experiments showed that in cell-free medium, at
pH 7.5 and 37°C, after 30, 60 and 90 min of incubation of TPT
(lactone), approximately 25%, 45% and 60% of the lactone was
converted to the hydroxy-acid form respectively. As the hydroxy-
acid is not taken up in the cells, the interconversion could influ-
ence the uptake data for TPT. For this reason, we used a relatively
short incubation period of 30 min in all our experiments. This
procedure yields approximately 75% of TPT still in the lactone
form at the end of the incubation, as was confirmed by the above-
mentioned HPLC analyses. Only small fluctuations in the pH of
the medium were noted in the incubation experiments (the pH was
below pH 8 in all cases), and these pH differences did not affect
the exposure of the cells to TPT in its lactone form within the
given exposure time. For quantitation of the accumulation of SN-
38 and CPT, 100 ,l of suspension was mixed with 50 Jtl of
MeOH/acetonitrile 1:1 (v/v) on ice. After mixing, the sample was
kept on ice for 10 min. Subsequently, 10 jl of a saturated zinc
sulphate solution in water was added. After mixing, the samples
were centrifuged at 4000g for 5 min. From the supematant,100 ,l
was injected on a hypersil ODS column (Shandon, Astmoor, UK).
SN-38 and CPT were eluted with [75 mm ammonium acetate/5
mM tetrabutylammoniumhydrogensulphate (pH 6.4)]/acetonitrile
(78/22). CPT and SN-38 were detected using fluorescence
detection (excitation wavelength 355 nm, emission wavelength
515 nm). Accumulation of the topo I drugs was determined in at
least three independent experiments and was expressed as pmol
topo I drug mg-' protein.
The accumulation process of TPT in the IGROV-1 and
IGROVT,a,, cell lines was also studied at0°C. The parental and resis-
tant cell lines were incubated for 30 min at0°C with 0.95 or 1.90gM
TPT. After this incubation, samples were treated as described above.
The influence ofthe P-gp-blocking agent VPL on the accumula-
tion of TPT in the IGROV-l and resistant IGROVTl00 cell lines
was evaluated by incubating the cells for 30 min simultaneously
with 1.90 ,M TPT and 1O ,M VPL. The effect of glutathione
depletion on the MRP-mediated efflux (Versantvoort et al, 1995;
Zaman et al, 1995) of TPT was tested by incubating cells with
50gM BSO for 24 hours followed by a 30-min incubation with
1.90 JM TPT. This concentration ofBSO did not affect viability of
the cells, whereas the glutathione levels were decreased to approx-
imately 20% of the normal levels. Intracellular accumulation of
TPT was assayed as outlined above.
Saturation kinetics of TPT in the IGROV-1 and
IGROVTl oor
In order to investigate the kinetics of TPT accumulation in the
IGROV-1 and IGROVTIOOr cell lines, cells were incubated with
TPT for 30 min at 37°C at concentrations ranging from 0.60 to
24 JM for the IGROV-1, and from 1.20 to 47 JM for the
IGROVTlIO cell line. Intracellular accumulation of TPT was
measured as described above.
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Figure 2 Immunocytochemical staining of P-gp and MRP1 expression in the IGROV-1 and IGROVTlOOr cell lines. The positive controls 2780AD and GLC4/ADR
(overexpressing P-gp and MRP respectively) are also included in this figure. (A) Cytospin preparation of 2780AD, stained for P-gp. (B) Cytospin preparation of
IGROV-1 and (C) of IGROVTlOOr, stained for P-pg. (D) Cytospin preparation of GLC4/ADR, stained for MRP1. (E) Cytospin preparation of IGROV-1 and (F) of
IGROVTl10r, stained for MRP1
Efflux of TPT
In order to measure the efflux of TPT from the IGROV-1 and the
IGROVTIOO cell lines, cells were loaded with TPT for 30 min with
470 nm and 3.55 ,UM, respectively, resulting in similar intracellular
concentrations of the drug. After exposure to TPT, cells were
washed twice with PBS at 37°C, resuspended in 4 ml of
prewarmed drug-free RPMI medium and incubated at 37°C. In
order to determine the efflux kinetics of TPT, flasks were with-
drawn directly after the washing procedure and after 5-, 10- and
20-min incubation in drug-free medium. Cells were washed with
PBS, harvested and the intracellular concentration of TPT at
these time-points was determined as outlined above. The experi-
ment was also performed at 0°C. In this experiment, cells
were loaded with TPT at 370C as described above, subsequently
washed with ice-cold PBS and incubated further at 0°C. The intra-
cellular concentration of TPT was determined directly after
the washing procedure and after a 10-min incubation in drug-
free medium.
Energy dependence of accumulation
Energy dependence of TPT accumulation in IGROV-1 and
IGROVTIOOr cells was investigated by transferring the cells to
RPMI 1640 medium, containing 10 mm sodium azide and 2-
deoxy-d-glucose insteadofglucose, for 15 min (Versantvoort etal,
1992). This procedure resulted in adecreased intracellularconcen-
tration ofATP to approximately 10% ofthe original concentration.
After this energy-depleting step, TPT (1.90 gM) was added to the
energy-depleted medium, and cells were incubated at 370C for
30 min. Samples were analysed as described above.
Energy dependence of efflux
The energy dependence of TPT efflux from the IGROV-1 and
IGROVTIOOr cell lines was studied by incubating these cells, which
had been transferred 15 min before incubation to the above-
described energy-deprived medium, with 470 nm or 3.55 giM TPT,
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Figure 3 Western blot of topo in IGROV-1 and IGROVT100r* Samples of
1 X 105 cells were separated using SDS-PAGE and subsequently
electrophoretically transferred to PVDF membrane. The blot was probed with
monoclonal anti-Topo as primary, and 1251-Protein A as secondary antibody.
Blots were scanned using a phosphor imaging system
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Figure 7 Accumulation of TPT in the IGROV-1 (0) and IGROVT0,0 (0) cell
lines, after exposure to increasing extracellular concentrations of TPT
1 o 2 D 5 6 7 8 9 1 11 12 1 3
1 2 3 4 5 6 7 8 9 10 11 12 13
Statistical analysis
Statistical evaluation was performed using the Student t-test and
Pearson correlation analysis. P-values < 0.05 were considered to
be significant.
IGROVT1OOr
Figure 4 Topo catalytic activity in the IGROV-1 and IGROVT,OO, cell lines.
Catalytic activities were determined using serial dilutions of nuclear extracts,
with protein concentrations ranging from 2.3 to 75 mg ml-', as described in
Materials and methods
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Figure 5 Inhibition of topo relaxation in the IGROV-1 and IGROVT100r cell
lines by CPT, determined as described in Materials and methods
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Figure 6 Accumulation of TPT in the IGROV-1 and IGROVT,r cell lines
after exposure to 0.95 or 1.90 gM TPT. IGROV-1, E; IGROVTIu,,r
respectively, for 30 min at 37°C. Subsequently, cells were washed
twice with PBS at 37°C, and cells were incubated in drug-free
energy-deprived medium for 0, 5, 10 or 20 min. At these time
points, flasks were withdrawn and TPT intracellular concentration
was analysed as described above.
RESULTS
IGROVTlWr cell line: resistance to TPT and
cross-resistance pattern
The IGROVTlOOr cell line displayed a 29-fold resistance to TPT
(Figure 1 and Table 1). This cell line showed cross-resistance to
SN-38 (51-fold) and to MX (32-fold), whereas only minor cross-
resistance to CPT was found. Minor or no cross-resistance to the
topo II inhibitors DOX and VP-16, nor to CDDP, paclitaxel and
5-FU, was observed. The IGROVTlIM cells appeared to be hyper-
sensitive to MTX. IC50 values for the resistant IGROVT)OOr and
sensitive IGROV-1 cell lines are summarized in Table 1.
Expression of P-gp and MRP1
Using immunocytochemistry, no expression of P-gp was noted in
the resistant IGROVTlOO and parental cell lines (Figure 2). About
20% ofthe IGROVTlOOr and 10% ofthe IGROV-1 cells stained for
mainly cytoplasmic MRP1 (Figure 2). MRP1-mediated staining in
these cell lines was very weak, compared with the staining that
was observed in the MRP1-overexpressing GLC4/ADR cell line
(Zaman et al, 1993), which was used as positive control.
Topo I protein levels, catalytic activity and stabilization
of topo I cleavable complex by CPT
Western blots of topo I in the IGROV-1 and IGROVTI,, cells are
shown in Figure 3. No significant differences in topo I levels between
IGROV-1 and IGROVTl1 were observed. Furthermore, no apparent
differences in topo I catalytic activity was observed between the two
cell lines (Figure 4). In both cell lines, topo I-mediated relaxation of
supercoiled pBR322 DNA was inhibited by concentrations of25 gM
CPT and higher for both cell lines (Figure 5).
Intracellular accumulation of TPT, SN-38 and CPT in the
IGROV-1 and IGROVTlOOr
Results ofthe TPT accumulation experiments in the IGROV- 1 and
IGROVTlOOr cell lines are shown in Figure 6. At extracellular TPT
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Table 2 Accumulation of SN-38 and CPT in IGROV-1 and IGROVT100r cells
after incubation with 1.02gM SN-38 or with 2.30 grm CPT for 30 min at 370C
SN-38 CPT
(pmol mg-' protein) (pmol mg-1 protein)
IGROV-1 30.8 ± 17.0 9.3 ± 1.9
IGROVT100r 11.2 ± 6.2 10.6 ± 3.6
After harvesting the cells, accumulation of SN-38 and CPT was measured as
described in Materials and methods. Values are means ± s.d. of at least
three independent experiments.
Table 3 Relative accumulation of TPT in IGROV-1 and IGROVT100, cells in
the absence and the presence of 10gM VPL or 50gM BSO, and the effect of
BSO on accumulation of TPT in the GLC4 and the MRP-overexpressing
GLC4 ADR cells
Normal (%) 10gM VPL (%) 50gM BSO (%)
IGROV-1 100 84.5 ± 6.5 (3) 81.7 ± 16.3 (4)
IGROVT1Or 15 16.8 ± 5.4 (3) 31.3 ± 4.0 (5)
GLC4 100 NMa 107 ±24 (3)
GLC4/ADR 68.7 NM 99.0 ± 21.3 (3)
aNM, not measured Cells were incubated with 1.90 iM TPT for 30 min at
370C. Next, cells were harvested, and accumulation was measured as
described in Materials and methods. Values are means ± s.d. of n (in
parentheses) independent experiments.
concentrations of 0.95 and 1.90gM, accumulation in the
IGROVTl,OOr cell line was approximately 85% lower than in the
parental cell line (P < 0.001). The average cell diameter, as deter-
mined using a CASY 1 cell counter (Scharfe System, Reutlingen,
Germany), ofthe IGROV-l andIGROVTIOOr cells is 15.1 ± 0.3 and
16.2 ± 0.6 jm, which yields a 23% increased volume of the
IGROVTIM compared with the IGROV-1. Protein content per cell
in the IGROVTIOlr is approximately 1.5-fold higher than in
IGROV-1 (575 vs 390 jg protein l0C cells respectively).
Therefore, the difference in accumulation between the IGROV-1
andIGROVTIM cell lines still exists on apercell basis. Notably, in
the IGROV-1 andIGROVTIM cell lines, no saturation kinetics was
observed up to TPT concentrations of 24 and 47 jM respectively
(Figure 7).
The accumulation of SN-38 in the IGROVTIOOr cell line was
decreased to 36% of that in the IGROV-1 (Table 2). However, no
decreased accumulation was observed for CPT in the resistant
IGROVTlOOr cell line.
Effects of VPL and BSO on the cellular accumulation
of TPT
In order to investigate whether reduced TPT accumulation was
mediated through MDR-related P-gp or MRP1, cells were treated
with the P-gp-blocking agent VPL (10 jM) or glutathione-
depleting BSO (50 jM). Simultaneous incubation of TPT with
10 jM VPL did not significantly influence the intracellular accu-
mulation of TPT in the IGROV-1 or IGROVTIOOr cell lines (Table
3), demonstrating that P-gp is not involved in the reduced accumu-
lation of TPT in the IGROVTIOOr cell line. Also MRP1 is not the
major cause of reduced accumulation, as depletion of glutathione
by a 24-h preincubation of the IGROVTIOO with BSO affected the
accumulation ofTPT only to a limited extent (Table 3).
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Figure 8 Efflux of TPT from IGROV-1 (0) and IGROVTlWr (0) cells after
loading the cells with 470 nm and 3.55gM TPT respectively. Efflux of TPT
was monitored at 00C and 370C. Intracellular concentrations of TPT were
determined as described in Materials and methods
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Figure 9 Relative accumulation of TPT in the IGROV-1 and the IGROVTl,or
cell lines at 370C, at 00C or under energy-depleting conditions. Cells were
incubated with 1.90gM TPT. Uptake of TPT in IGROV-1 at 370C was taken
as 100%. 370C, 0; 0°C, *; under energy-depleting conditions, rO
Notably, accumulation of TPT in the GLC4/ADR cell line,
which was used as positive control for MRP expression, was
reduced to only approximately 69% of the accumulation in the
parental GLC4 (Table 3). In the GLC4/ADR cell line, accumulation
was completely restored upon incubation with BSO. This finding
supports the conclusion that MRP overexpression in the
IGROVTlOO cell line is not sufficient to explain the reduced
accumulation in this cell line.
Efflux of TPT from the parental IGROV-1 and IGROVT,OOr
cell lines
A very rapid efflux ofTPT was observed both in the IGROV-I and
the IGROVTlOOr cell lines (Figure 8). More than 90% of the intra-
cellular compound is transported out of the cell within 20 min of
incubation in drug-free medium. The efflux rates of TPT in the
IGROV-1 and IGROVTlft were not significantly different, with
half-lives of3.38 ±0.82 and 2.66± 0.53 minrespectively (P = 0.14).
Accumulation and efflux at lower temperature
In order to assess the role of active transport in the kinetics ofTPT,
accumulation and efflux of TPT were assayed at 0°C. As shown in
Figure 8, the efflux of TPT from the parental IGROV-1 and
IGROVTI,0, cells was completely inhibited in preloaded cells by
lowering the temperature to 0°C. Data on the accumulation ofTPT
(1.90jM) at370C and0°C are shown in Figure 9. At0°C, accumula-
tion in the parental IGROV-I cell line was only 7.3% ofthe accumu-
lation at 370C (P < 0.001). In theIGROVTI, cell line, accumulation
at0°C was lowered to approximately 50% ofits value at 37°C.
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Transport of TPT under energy-deprived conditions
Accumulation of TPT in IGROV-1 cells under conditions of
energy depletion by azide and 2-deoxy-d-glucose was decreased
relative toenergy-proficient conditions, whereas in theIGROVTIOOr
the accumulation under these energy-depleting conditions was
increased (Figure 9). Efflux of TPT appears to be only partly
energy dependent, as depletion ofenergy did not have a significant
effect on efflux rates in the IGROV-1 and IGROVTlft cell lines
(data not shown).
DISCUSSION
We developed the TPT-resistant humanIGROVTlOOr ovarian cancer
cell line, which is cross-resistant to SN-38 but displays only minor
resistance to CPT. Resistance to these CPT analogues has been
attributed to reduced expression or reduced activity oftopo I (Eng
et al, 1990; Sugimoto et al, 1990; Madelaine et al, 1993; Fujimori
et al, 1995), but this is not the case for the IGROVTIOOr cell line, as
protein levels and catalytic activity of topo I in the IGROV-1 and
IGROVTIM cell lines are equal. Furthermore, cleavable complex
formation in both cell lines is equally sensitive to CPT.
Resistance to TPT and SN-38 in the IGROVTIM cell line
appears to be caused by reduced accumulation of the respective
compounds. The importance of reduced accumulation is further
suggested by the unchanged accumulation characteristics of CPT
in the IGROVT,OOr cell line, accompanied by an almost lack of
resistance ofthe cells for this compound.
Multidrug resistance has been associated with an increased
expression ofP-gp and MRP1, yielding reduced intracellular accu-
mulation ofdrugs. P-gphasbeen shown tobeinvolved inresistance
to TPT, as acquired resistance to TPT was accompanied by
increased expression ofP-gp and reduced accumulation (Hendricks
et al, 1992). However, in the IGROVTIM cell line, no over-
expression of P-gp was observed. Furthermore, no P-gp-related
MDR characteristics are present in theIGROVTm cell line, as no
cross-resistance to other drugs except MX is observed. Also the
absence of a stimulating effect of VPL on accumulation of TPT in
this cell line argues against the involvement of P-gp in the mecha-
nism of resistance of TPT and SN-38. Also MRP1, which is
expressed in about 20% ofthe resistant cells, does not appear to be
critical in relation to the acquired reduced accumulation and resis-
tance in theIGROVT100,. cell line, as the cell line does not show an
MDR phenotype (Table 1). Moreover, inhibition of MRP1 by
depletion ofglutathione does not result in complete reversal ofthe
reduced accumulation ofTPT in theIGROVTI00r cells.
We propose that our data are consistent with the hypothesis that
an energy-dependent influx system for TPT and SN-38 is present
in the IGROV-l cell line but is defective in the IGROVTIM cell
line. The following points support this hypothesis. The efflux of
TPT from the IGROV-1 as well as the IGROVTlIt cells was
completely inhibited by lowering the temperature to 0°C.
Lowering of the temperature also resulted in the almost complete
inhibition of the accumulation of TPT in the IGROV-1 cell line.
However, accumulation of TPT in the resistant IGROVTIOOr cell
line was decreased to a lesser extent at 0°C, compared with accu-
mulation at 37°C in this cell line. This indicates that in the
IGROVT,OOr a significant portion of TPT apparently accumulates
by temperature-independent, and therefore presumably energy-
independent, processes, whereas in the IGROV-1 a major part of
TPT is accumulated by temperature-dependent processes.
Strikingly, the accumulation ofTPT at 0°C was similar in both cell
lines. The energy dependence ofTPT accumulation in the IGROV-
1 cell line was further indicated by the energy depletion experi-
ment, which yielded a decreased accumulation of TPT in the
IGROV-1 cell line. However, accumulation of TPT in the
IGROVTIOOr cell line under energy-deprived conditions was
increased. As efflux characteristics of TPT in the IGROV-1 and
IGROVTift cell lines are not significantly different, the difference
in intracellular accumulation may be explained by an energy-
dependent inward transport system in the IGROV-l cell line that is
capable of transporting TPT and SN-38 but, however, is not able
to transport CPT. Probably such a system is hampered in the
IGROVTlft cell line. This mechanism of resistance to topotecan
and SN-38 has not been described before. However, for other
drugs, i.e. the vinca alkaloids, energy-dependent influx has been
observed (Sirotnak et al, 1986). Furthermore, abrogation of that
uptake route was shown to result in resistance to, for example,
vincristine (Sirotnak et al, 1986).
Recently, Yang et al (1995) reported an MX-resistant breast
carcinoma MCF7 cell line that, surprisingly, displayed a selective
cross-resistance against TPT and SN-38, but lacked resistance to
CPT (Yang et al, 1995). Although no data are available concerning
the accumulation of these CPT derivatives in this MCF7 cell line,
the similar cross-resistance patterns in this MCF7/MX and our
IGROVTlO, cell line suggest thatthe resistance in these cell lines is
mediated by the same type ofmechanism.
In conclusion, we developed a TPT-resistant IGROV-1 human
ovarian tumour cell line that displays significant cross-resistance
to SN-38, butis only marginally resistant to CPT. The resistance is
accompanied by decreased accumulation of TPT and SN-38, and
is not mediated by P-gp or MRP1. The net energy-dependent
efflux of TPT in the IGROV-1 andIGROVTIO,, cell lines was not
significantly different. In addition, no significant differences have
been observed between energy-independent efflux of TPT in the
parental and the resistant cell line. We hypothesize that the resis-
tance to TPT in theIGROVTlO is caused by reduced influx. In our
laboratory, work has started that is aimed at a further characteriza-
tion of this accumulation defect of TPT and SN-38 in the
IGROVTIOOr cell line.
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ABBREVIATIONS
BSO, DL-buthionine-(S,R)-sulfoximine; CDDP, cisplatin; CPT,
camptothecin; DOX, doxorubicin; 5-FU, 5-fluorouracil; MAb,
monoclonal antibody; MRP, multidrug resistance-associated
protein; MTX, methotrexate; MX, mitoxantrone; PBS, phosphate-
buffered saline; P-gp, P-glycoprotein; SRB, sulforhodamine B;
TPT, topotecan; topo I, topoisomerase I; VPL, verapamil
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